Cargando…

The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination

As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are also accelerating. This longitudinal serolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benschop, Robert J., Tuttle, Jay L., Zhang, Lin, Poorbaugh, Josh, Kallewaard, Nicole L., Vaillancourt, Peter, Crisp, Melissa, Trinh, Thi Ngoc Vy, Freitas, Joshua J., Beasley, Stephanie, Daniels, Montanea, Haustrup, Natalie, Higgs, Richard E., Nirula, Ajay, Cohen, Myron S., Marovich, Mary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210450/ https://www.ncbi.nlm.nih.gov/pubmed/35679357 http://dx.doi.org/10.1126/scitranslmed.abn3041

Ejemplares similares

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab
por: Sims, Jonathan T., et al.
Publicado: (2022)

First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19
por: Chen, Peter, et al.
Publicado: (2021)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021)

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2
por: Nathan, Ramesh, et al.
Publicado: (2021)

COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine
por: Huhn, Gregory, et al.
Publicado: (2022)

A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clinical Trial
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

Longitudinal assessment of systemic steroid therapy on hyperinflammatory endothelial biomarker profiles and serology responses of COVID-19 patients
por: Sims, Jonathan T., et al.
Publicado: (2022)

BAMLANIVIMAB-INDUCED GUILLAIN-BARRÉ SYNDROME
por: PALAGUACHI, GLADYS, et al.
Publicado: (2021)

146. Intact Sense of Taste and Smell During COVID-19 Infection Is Associated with Absence of of SARS-CoV-2 Spike Protein Antibody Responses within 3 Months of Symptomatic Illness
por: Wilson, James M, et al.
Publicado: (2021)

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

Bamlanivimab Monoclonal Antibody Treatment in Patients with Graft Versus Host Disease (GVHD) Diagnosed with COVID-19 Infection
por: Faisal, Muhammad Salman, et al.
Publicado: (2022)

Bamlanivimab: Guillain-Barre syndrome: case report
Publicado: (2021)

Bamlanivimab: New-onset seizures: case report
Publicado: (2022)

Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies
por: Laurini, Erik, et al.
Publicado: (2021)

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
por: Chew, Kara W., et al.
Publicado: (2022)

Bamlanivimab infusion experience at one academic emergency department
por: Yoo, Michael J., et al.
Publicado: (2022)

Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19
por: Destras, Grégory, et al.
Publicado: (2021)

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab
por: Okragly, Angela J., et al.
Publicado: (2023)

Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Bariola, J Ryan, et al.
Publicado: (2021)

Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report
por: Pillai, Rajapillai L. I., et al.
Publicado: (2023)

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
por: Chew, Kara W., et al.
Publicado: (2023)

Bamlanivimab for Mild to Moderate COVID-19 in Kidney Transplant Recipients
por: Jan, Muhammad Y., et al.
Publicado: (2021)

Real World Utilization of Bamlanivimab at a Rural Community Hospital
por: Leavitt, Rachael, et al.
Publicado: (2021)

542. Use of Bamlanivimab in Cancer Patients with Mild-to-Moderate COVID-19
por: Brock, Patricia, et al.
Publicado: (2021)

Interleukin-33 Contributes Toward Loss of Tolerance by Promoting B-Cell-Activating Factor of the Tumor-Necrosis-Factor Family (BAFF)-Dependent Autoantibody Production
por: Rose, William A., et al.
Publicado: (2018)

Evaluation of plasma IL-21 as a potential biomarker for type 1 diabetes progression
por: Schroderus, Anna-Mari, et al.
Publicado: (2023)

530. Bamlanivimab (BAM) for SARS-CoV-2 Infection: Rates and Risk Factors for Hospitalization after Monoclonal Antibody Administration in a High-Risk Population
por: Curtin, John M, et al.
Publicado: (2021)

Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection
por: Bavaro, DF, et al.
Publicado: (2022)

A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
por: Dougan, Michael, et al.
Publicado: (2021)

Development of a Bamlanivimab Infusion Process in the Emergency Department for Outpatient COVID-19 Patients
por: Pham, Danny H., et al.
Publicado: (2021)

The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
por: Corwin, Douglas S, et al.
Publicado: (2021)

506. Outpatient Bamlanivimab, Casirivimab and Imdevimab for COVID-19: Single Center Feasibility Analysis
por: Chundi, Vahini, et al.
Publicado: (2021)

Bamlanivimab: Gene mutation in COVID-19 infection and off label use: case report
Publicado: (2022)

PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together
por: Ernest, C. Steven, et al.
Publicado: (2022)

Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report
por: Daher, Ayham, et al.
Publicado: (2021)

Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study
por: Alam, Mohammud M, et al.
Publicado: (2021)

Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19
por: Melton, James D., et al.
Publicado: (2021)

Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community
por: Iqbal, Leena, et al.
Publicado: (2021)

Bamlanivimab: Transfusion-related acute lung injury following off label use: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b4tbvncm8492pj1ndj02842opu